hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06373575, orgStudyIdInfo id: 2023-SR-891, briefTitle: IVC and Lung Ultrasound B-lines Guided Decongestion in Critically Ill ESKD Patients With Heart Failure, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-04-30, completionDateStruct date: 2025-06-30, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: The First Affiliated Hospital with Nanjing Medical University, class: OTHER, descriptionModule briefSummary: The objectives of this trial are to determine whether, in critically ill ESKD patients randomization to fluid removal guided by lung and inferior vena cava ultrasound, compared to standard care, leads to Improved pulmonary congestion (primary outcome); and safety (secondary outcome) in the short-term., conditionsModule conditions: End-stage Renal Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Lung and inferior vena cava ultrasound guidance, interventions name: Conventional protocol guidance, outcomesModule primaryOutcomes measure: Improvement in pulmonary congestion score, primaryOutcomes measure: Improvement in heart failure symptoms score, secondaryOutcomes measure: Total ultrafiltration volume, secondaryOutcomes measure: Mean ultrafiltration rate during prolonged hemodialysis, secondaryOutcomes measure: Fluid balance (total outflow - total inflow), secondaryOutcomes measure: Lung B-line reduction, secondaryOutcomes measure: The change of width of inferior vena cava, secondaryOutcomes measure: Incidence of hypotension during prolonged hemodialysis, secondaryOutcomes measure: Blood pressure variability during the prolonged hemodialysis, secondaryOutcomes measure: In-hospital mortality, secondaryOutcomes measure: Length of hospital stay, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Jiangsu Province Hospital, city: Nanjing, state: Jiangsu, zip: 210029, country: China, geoPoint lat: 32.06167, lon: 118.77778, hasResults: False
protocolSection identificationModule nctId: NCT06373562, orgStudyIdInfo id: Wrestlers, briefTitle: Effect of Hypoxic Exposure on Blood Variables in Elite Wrestlers, statusModule overallStatus: COMPLETED, startDateStruct date: 2013-12-02, primaryCompletionDateStruct date: 2013-12-18, completionDateStruct date: 2013-12-18, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Poznan University of Physical Education, class: OTHER, descriptionModule briefSummary: Twelve male wrestlers of the National Polish Team were observed in the study during the camp. The hypoxia group (n=6) participated in sports training and hypoxic exposure, while the control group (n=6) included wrestlers participating only in sports training. The hypoxic group lived and slept in hypoxic rooms. During the camp, all wrestlers followed the same training schedule and diet. In the blood were determined levels of creatine kinase (CK), C-reactive protein (hsCRP) concentration, nitric oxide (NO), morphology, reticulocytes, lipid profile, and ferritin. Also vascular endothelial growth factor (VEGF, VEGFR2, and VEGFR3), erythropoietin (EPO), angiopoietin (Ang 1, Ang 2), endothelial cell adhesion factor-1 (VCAM-1), Erythropoietin (EPO) and hypoxia-inducible factor 1 (HIF-1). Body weight composition was determined., conditionsModule conditions: Hypoxia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: SINGLE_GROUP, interventionModelDescription: Wrestlers in H group were living in hypoxic rooms for 8-14h/d and between that they were participating in sports training. C group was participating in the same training protocol., primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 12, type: ACTUAL, armsInterventionsModule interventions name: hypoxia, outcomesModule primaryOutcomes measure: CK, primaryOutcomes measure: hsCRP, primaryOutcomes measure: HIF-1, primaryOutcomes measure: EPO, primaryOutcomes measure: VEGF, VEGF 2, VEGF 3., primaryOutcomes measure: Ang 1, Ang 2, primaryOutcomes measure: VCAM-1, otherOutcomes measure: blood count, otherOutcomes measure: lipid profile, otherOutcomes measure: ferritin, otherOutcomes, eligibilityModule sex: MALE, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06373510, orgStudyIdInfo id: ELCAV, briefTitle: Longitudinal Evaluation of Antibody Kinetics of Vaccinated Patients With Non-mandatory Vaccine Following Administration of a Non-public Marketed Vaccine in the General Population, Real-life Study, acronym: ELCAV, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-20, primaryCompletionDateStruct date: 2027-04-03, completionDateStruct date: 2027-04-03, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: CerbaXpert, class: OTHER, descriptionModule briefSummary: The study would make it possible to document more explicitly the evolution of antibody titers at following a non-public vaccination over a large post-vaccination period in the French population .Analysis of real-life data would enhance knowledge of vaccine response kinetics It would be useful to identify possible early declines requiring doses Similarly, by analyzing antibody kinetics by age, sex, and vaccination status, the would be possible to determine whether there are differences in the immune response between these different sub-groups. In addition, it would provide additional information to assess the real impact of these non-public vaccines in public health and guide vaccine policies., conditionsModule conditions: Vaccination Reaction, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 10000, type: ESTIMATED, armsInterventionsModule interventions name: Blood collection, outcomesModule primaryOutcomes measure: Quantification of specific serum antibodies (IgM, IgG) at different times before and/or after vaccination by a reference technique such as ELISA., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06373484, orgStudyIdInfo id: 018-2022, briefTitle: Matching Assessment and Treatment for Children With Disruptive Behaviour and Their Parents, acronym: MATCH-DB, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-10-01, primaryCompletionDateStruct date: 2026-09, completionDateStruct date: 2027-09, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Centre for Addiction and Mental Health, class: OTHER, descriptionModule briefSummary: This study will develop and test whether personalized profiles of children with Disruptive Behaviour Disorder (DBD) and their parents based on important psychological, emotional, and neuropsychological indicators predict their response to child cognitive behavioral treatment and Behavioral Parent Training., conditionsModule conditions: Disruptive Behavior Disorder, conditions: Emotional Disorder, conditions: Behavioural Disorder, conditions: Attention Deficit Hyperactivity Disorder, conditions: Conduct Disorder, conditions: Oppositional Defiant Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Behavioral Parent Training, outcomesModule primaryOutcomes measure: Changes in parenting skills between baseline, post-treatment, and follow-up (6 months - 1 year), primaryOutcomes measure: Changes in parenting competencies between baseline, post-treatment, and follow-up (6 months - 1 year), primaryOutcomes measure: Changes in child emotional and behavioral problems between baseline, post-treatment, and follow-up (6 months - 1 year), eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 12 Years, stdAges: CHILD, contactsLocationsModule locations facility: Centre for Addiction and Mental Health, status: RECRUITING, city: Toronto, state: Ontario, zip: M6J 1H4, country: Canada, contacts name: Brendan F. Andrade, PhD, role: CONTACT, phone: 416-535-8501, phoneExt: 33642, email: brendan.andrade@camh.ca, geoPoint lat: 43.70011, lon: -79.4163, hasResults: False
protocolSection identificationModule nctId: NCT06373471, orgStudyIdInfo id: S-20230101, briefTitle: Improving Quality of Life in Older Patients With Frailty and Hematological Cancer Through Geriatric Assessment, acronym: IMPROVE, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-02, primaryCompletionDateStruct date: 2026-03-31, completionDateStruct date: 2026-09-30, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Odense University Hospital, class: OTHER, collaborators name: Velux Fonden, collaborators name: Danish Cancer Research Foundation, collaborators name: The Dagmar Marshall Foundation, descriptionModule briefSummary: The Improve study is a randomized controlled trial investigating the efficacy of adding comprehensive geriatric assessment and treatment to standard of care compared with standard of care in older, frail patients with hematological cancer. The investigators aim to recruit 152 study participants who will be randomized 1:1 to intervention- or control group. Study participants in the intervention group will receive the intervention comprehensive geriatric assessment and treatment integrated in the cancer treatment. Study participants in the control group will receive cancer treatment and evaluation of comorbidity and frailty as is usual standard at Department of Hematology. Primary endpoint is elderly functional Index at 12 weeks., conditionsModule conditions: Hematologic Malignancy, conditions: Treatment Adherence, conditions: Treatment Complication, conditions: Frailty, conditions: Quality of Life, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 152, type: ESTIMATED, armsInterventionsModule interventions name: Comprehensive geriatric assessment (CGA) and treatment, outcomesModule primaryOutcomes measure: Elderly functional Index, secondaryOutcomes measure: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)., secondaryOutcomes measure: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Elderly14 (EORTC QLQ-Eld14)., secondaryOutcomes measure: Handgrip strength, secondaryOutcomes measure: 30-second chair stand test, secondaryOutcomes measure: Treatment toxicity, secondaryOutcomes measure: Adherence to hematological cancer treatment, secondaryOutcomes measure: Polypharmacy yes/no, secondaryOutcomes measure: Unplanned hospital admissions, secondaryOutcomes measure: Overall and cancer specific survival, eligibilityModule sex: ALL, minimumAge: 70 Years, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Odense University Hospital, status: RECRUITING, city: Odense C, zip: 5000, country: Denmark, contacts name: Nina Andersen, M.D., role: CONTACT, phone: +4540437488, email: nina.andersen@rsyd.dk, geoPoint lat: 55.39594, lon: 10.38831, hasResults: False
protocolSection identificationModule nctId: NCT06373458, orgStudyIdInfo id: STUDY-23-01508, briefTitle: Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2026-03, completionDateStruct date: 2026-05, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Icahn School of Medicine at Mount Sinai, class: OTHER, collaborators name: Pfizer, descriptionModule briefSummary: Keloids are common, benign cutaneous overgrowths that manifest clinically as raised, hypertrophic, often hyperpigmented lesions which are formed in response to dermal injury or idiopathic stimuli. Although keloids are a common disease, it's exact incidence and prevalence is not known. Despite the debilitating nature of keloids, current treatment modalities are limited in efficacy; there is no universally effective therapy available to patients. The research team hypothesize that ritlecitinib as a JAK3/TEC inhibitor will be able to reverse both the systemic and local keloid disease process by re-establishing immune homeostasis., conditionsModule conditions: Keloid, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Ritlecitinib, outcomesModule primaryOutcomes measure: Recurrence Rate, primaryOutcomes measure: Change in Detroid Keloid Scale Score, secondaryOutcomes measure: Change in Peak keloid tension, secondaryOutcomes measure: Change in Detroid Keloid Scale Score (DKS), secondaryOutcomes measure: Change in Pain Numerical Rating Scale (Pain-NRS), secondaryOutcomes measure: Change in Itch-NRS, secondaryOutcomes measure: Change in PGIC (Patient Global Impression of Change), secondaryOutcomes measure: Change in DLQI (Dermatology Life Quality Index), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Icahn School of Medicine at Mount Sinai, status: RECRUITING, city: New York, state: New York, zip: 10029, country: United States, contacts name: Giselle Singer, role: CONTACT, phone: 212-241-3288, email: giselle.singer@mssm.edu, contacts name: Sharlene Martin, role: CONTACT, phone: 212-241-3288, contacts name: Emma Guttman, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 40.71427, lon: -74.00597, hasResults: False
protocolSection identificationModule nctId: NCT06373445, orgStudyIdInfo id: 36264PR596, briefTitle: Interventional Neuromodulation in Fibromyalgia, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-11-01, primaryCompletionDateStruct date: 2023-09-01, completionDateStruct date: 2024-04-15, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Tanta University, class: OTHER, descriptionModule briefSummary: This study was conducted on 40 eligible fibromyalgia patients with sleep disorders. They were randomized to have 20 sessions of active or sham rTMS (1 Hz, 120% of resting motor threshold with total 1200 pules /session) over the right dorsolateral prefrontal area (DLPFC) for 5 sessions/week for 4 weeks. All participants were subjected to baseline evaluation with Fibromyalgia Impact Questionnaire, polysomnography, sleep quality and sleep characteristics assessment using the Pittsburgh Sleep Quality Index and The Medical Outcomes Study Sleep Scale respectively.FM patients were reevaluated at 1, 3 months after the end of rTMS sessions., conditionsModule conditions: Neuromodulation and Sleep Disorders, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: FACTORIAL, interventionModelDescription: participants randomly allocated to either no, one, some or all interventions simultaneously, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: CARE_PROVIDER, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: repetitive transcranial magnetic stimulation active stimulation, interventions name: repetitive transcranial magnetic stimulation sham stimulation, outcomesModule primaryOutcomes measure: Pittsburgh Sleep Quality Index (PSQI), primaryOutcomes measure: The Medical Outcomes Study Sleep Scale (MOS ), primaryOutcomes measure: polysomnography, secondaryOutcomes measure: Pittsburgh Sleep Quality Index (PSQI), secondaryOutcomes measure: The Medical Outcomes Study Sleep Scale (MOS), secondaryOutcomes measure: polysomnography, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Faculty of medicine, status: RECRUITING, city: Tanta, state: ElGharbia, zip: 6620010, country: Egypt, contacts name: Marwa Y Badr, role: CONTACT, phone: 01003639125, phoneExt: Tanta, email: drmoroneuro@yahoo.com, geoPoint lat: 30.78847, lon: 31.00192, hasResults: False
protocolSection identificationModule nctId: NCT06373432, orgStudyIdInfo id: STUDY-22-01607, briefTitle: Frequency of Glucose Monitoring in Labor, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-11-26, completionDateStruct date: 2024-11-26, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Icahn School of Medicine at Mount Sinai, class: OTHER, descriptionModule briefSummary: The aim of this study is to assess rates of neonatal hypoglycemia with differing intrapartum glucose protocols. Currently at this time there is no guidance from professional medical organizations about when and how frequent to assess maternal glucose levels intrapartum. Several institutions have no protocols in place. The study will be a randomized controlled trial placing patients with Gestational Diabetes Mellitus (GDM) in "frequent" vs "infrequent" glucose monitoring intrapartum and assessing neonatal glucose levels at birth., conditionsModule conditions: Neonatal Hypoglycemia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: DOUBLE, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 160, type: ESTIMATED, armsInterventionsModule interventions name: Fingerstick, outcomesModule primaryOutcomes measure: Neonatal Hypoglycemia, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mount Sinai West Hospital, city: New York, state: New York, zip: 10019, country: United States, geoPoint lat: 40.71427, lon: -74.00597, hasResults: False
protocolSection identificationModule nctId: NCT06373419, orgStudyIdInfo id: RP-1007, briefTitle: TFL vs MOSES Holmium Laser in the En-bloc Resection of Bladder Tumors, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-10-16, primaryCompletionDateStruct date: 2025-10, completionDateStruct date: 2026-10, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Thunder Bay Regional Health Research Institute, class: OTHER, descriptionModule briefSummary: The goal of this randomized clinical trial is to determine if there is difference in pathological and clinical outcomes between MOSES and TFL in the transurethral laser enucleation of bladder tumors.The main question it aims to answer is:Is there a difference in pathological and clinical outcomes between MOSES Holmium and Thulium Fiber Laser (TFL) in the transurethral laser enucleation of bladder tumors?Participants will randomized to either TFL of MOSES arm for their bladder resection procedure., conditionsModule conditions: Urolithiasis of Bladder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: TFL, interventions name: MOSES holmium laser, outcomesModule primaryOutcomes measure: Presence of muscularis propria, primaryOutcomes measure: Incidence of inconclusive pathology, secondaryOutcomes measure: Tumor-free rate (TFR), secondaryOutcomes measure: Total operative time, secondaryOutcomes measure: Total procedural time, secondaryOutcomes measure: Number of recurrences, secondaryOutcomes measure: Total blood loss, secondaryOutcomes measure: Rate of complications, secondaryOutcomes measure: Number of inconclusive pathology, secondaryOutcomes measure: Lasing time, secondaryOutcomes measure: Total energy used, secondaryOutcomes measure: Frequency and severity of peri-operative complications, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Thunder Bay Regional Health Sciences Centre, status: RECRUITING, city: Thunder Bay, state: Ontario, zip: P7B 6V4, country: Canada, contacts name: Rabail Siddiqui, role: CONTACT, phone: (807) 684-6000, email: rabail.siddiqui@tbh.net, contacts name: Hazem Elmansy, role: SUB_INVESTIGATOR, geoPoint lat: 48.38202, lon: -89.25018, hasResults: False
protocolSection identificationModule nctId: NCT06373406, orgStudyIdInfo id: MHB036C-CP001CN, briefTitle: A Study of MHB036C for Advanced Solid Tumor, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-05-18, primaryCompletionDateStruct date: 2024-08, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: Minghui Pharmaceutical (Hangzhou) Ltd, class: INDUSTRY, descriptionModule briefSummary: Phase I/II, dose escalation and dose expansion study to evaluate the efficacy and safety of MHB036C in advanced malignant tumors., conditionsModule conditions: Advanced Solid Tumor, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: MHB036C, outcomesModule primaryOutcomes measure: Incidence of participants with adverse events (AE), primaryOutcomes measure: Number of participants with dose-limiting toxicity (DLT), secondaryOutcomes measure: Maximum Plasma Concentration (Cmax), secondaryOutcomes measure: The area under the plasma concentration-time curve (AUC), secondaryOutcomes measure: To detectable anti-drug antibodies with treated subjects, secondaryOutcomes measure: Objective response rate (ORR), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Shanghai Chest Hospital, status: RECRUITING, city: Shanghai, zip: 200030, country: China, contacts name: Shun Lu, MD, role: CONTACT, phone: 13601813062, email: shun_lu@hotmail.com, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False